ClinicalTrials.gg
CompletedNCT01244217Updated Oct 16, 2013

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)

A Phase 2/3 interventional study of fexofenadine/Allegra (M016455) in Rhinitis Perennial, sponsored by Sanofi. Completed at 15 sites in Japan. Open to participants aged 6 Months to 11 Years. Per ClinicalTrials.gov, last updated 2013-10-16.

Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
6 Months to 11 Years
Sex
All
01

Study summary

Primary Objective:

  • To evaluate safety (4 weeks)

Secondary Objectives:

  • To evaluate the long-term safety (12 weeks)
  • To evaluate the efficacy
  • To characterize the pharmacokinetic profile
Read the detailed description

The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.

02

Conditions studied

  • Rhinitis Perennial

Browse trials for

03

In context

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

This study's enrollment of 100 is above the median of 80 across 187 interventional studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 months through 11 years
  • Patients with perennial allergic rhinitis

Exclusion criteria

Exclusion criteria:

  • Neither serum specific IgE antibody or skin reaction is positive for the antigen of perennial allergy.
  • Nasal symptom score is 0 for either sneezing or nasal discharge, or sum of these two score is less than 3, or nasal congestion score is 4.
  • Patients with vasomotor rhinitis or eosinophilic rhinitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Age 6 months - 2 years

    Patients between 6 months and 2 years old

    Drug: fexofenadine/Allegra (M016455)

  • Experimental
    Age 2 - 11 years

    Patients between 2 and 11 years (and under 10.5 kg)

    Drug: fexofenadine/Allegra (M016455)

  • Experimental
    Age 2 - 11 years (and over 10.5 kg)

    Patients between 2 and 11 years (and over 10.5 kg)

    Drug: fexofenadine/Allegra (M016455)

Interventions

  • Drugfexofenadine/Allegra (M016455)

    Drug page: Fexofenadine

    Pharmaceutical form:dry syrup formulation to be suspended in water Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events

    Time frame: 4 weeks

  2. The number of clinically significant abnormalities for laboratory findings

    Time frame: 4 weeks

Secondary outcomes

  1. Number of patients with adverse events

    Time frame: 12 weeks

  2. The number of clinically significant abnormalities for laboratory findings

    Time frame: 12 weeks

  3. Changes from baseline in nasal symptom scores on patient diary

    Time frame: 4 weeks

  4. Changes from baseline in nasal symptom severity scores assessed by investigator or subinvestigator

    Time frame: week 2 and 4

  5. Pharmacokinetic parameters of fexofenadine at steady state; AUC

    Time frame: week 4 and 12

07

Study locations

15 sites
  • Sanofi-Aventis Investigational Site Number 392015
    Fukuoka-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392012
    Kanazawa-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392001
    Kawaguchi-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392003
    Kawasaki-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392004
    Kawasaki-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392002
    Kita-Ku, Japan
  • Sanofi-Aventis Investigational Site Number 392011
    Kofu-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392014
    Obu-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392013
    Seki-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392005
    Yokohama-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392006
    Yokohama-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392007
    Yokohama-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392008
    Yokohama-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392009
    Yokohama-Shi, Japan
  • Sanofi-Aventis Investigational Site Number 392010
    Yokohama-Shi, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Nov 19, 2010
Start
Oct 2010
Primary completionActual
Jul 2011
CompletionActual
Aug 2011
Last update
Oct 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01244217
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 19, 2010
Start date
Oct 2010
Primary completion
Jul 2011
Completion
Aug 2011
Last update
Oct 16, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion